fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

PPI Hits & Thursday’s Stock Market Goes On A Ride – $AAPL $INM $INVO $KDNY $SSI $TSLA Rise!

By John F. Heerdink, Jr.
Quote of the Day – “History is a vast early warning system.” – Norman Cousins
 

On Thursday, the stock market digested a number of macroeconomic reports that helped bring about a bit of confusion in investors’ minds and served to increase volatility throughout the session. First, there was the June PPI, which rolled in at 1.1% and greater than expected, however the June Core PPI came in at .4% & slightly lower than expected. The June report also raised the Y/Y PPI rate to 11.3%. The Weekly Initial Claims report also confirmed an increase at 244K, while the Weekly Continuing Claims came in at 1.331M. The Weekly EIA Natural Gas Inventories report confirmed a build of 58 bcf . 

At the end for the trading session, 8 of the 11 sectors ended the day in the red with only the information technology sector moving up .9%, the consumer staples moving up .2% & the utilities sector ticking up .01%. The financials were the biggest losers of the day dropping 1.9% as JPMorgan Chase (JPM, $108, -3.5%) & Morgan Stanley (MS, $74.69, +0.4%) reported their earnings and missed Wall Street’s expectations.  In addition, Jamie Dimon, CEO of JPMorgan gloomily stated, “In our global economy, we are dealing with two conflicting factors, operating on different timetables. The U.S. economy continues to grow and both the job market and consumer spending, and their ability to spend, remain healthy. But geopolitical tension, high inflation, waning consumer confidence, the uncertainty about how high rates have to go and the never-before-seen quantitative tightening and their effects on global liquidity, combined with the war in Ukraine and its harmful effect on global energy and food prices are very likely to have negative consequences on the global economy sometime down the road.”  Interestingly, the yield curve remained inverted as the 2-yr treasury yield closed down 1 basis point at 3.12%, while the 10-yr yield also moved up 6 basis points to close at 2.96%. 

As a result, the major indices went on a bit of a roller coaster ride today as they edged higher out of the gate, then fell precipitously through the meat of the day, and then rose into the close. The S&P 500 closed at 3,790.38 (-.30%), the Dow ended the session at 30,630.17 (-.46%), but the Nasdaq managed to close higher at 11,251.185 (+.03%). The Nasdaq saw decliners outpace the advancers by a margin of 2-1, while the NYSE realized a 14-5 margin.  

The small caps on the Russell 2000 took a solid hit and closed at 1,707.51 (-1.07%). The MicroCaps closed sharply lower across the board as the iShares Micro-Cap ETF (IWC) closed at $106.20, -1.17%. Biotech stocks also traded significantly lower on the lower end of the spectrum as the SPDR S&P Biotech ETF (XBI) closed at $81.32, -2.31%. The 52-wk range is now $61.78 – $136.61. The iShares Biotechnology ETF (IBB) closed at $121.47, -1.68%. The 52-range is $104.29 – $177.37.

A decent measure of the markets volatility or the CBOE Volatility Index (^VIX) cooled off today closing at $26.40, down 1.57% and traded within the range of $26.30 – $28.45.

Around the money and precious metals’ tree, the U.S. Dollar Index closed uncomfortably high at 108.53, -.01%, while Bitcoin (BTC) bounced back over 20k to $20,469.28, +1.12% over the last 24-hours at the time of this writing. Gold prices closed at $1,710/oz.,-$26/oz. & silver closed at $18.44/oz., -$.76/oz. on the day. Two mining producers closed the day as follows: Hecla Mining Company (HL) closed at $3.69, -5.87% and First Majestic Silver Corp. (AG) closed at $6.89, -3.77%. On July 12, Hecla Mining  announced its preliminary production for the second quarter of 2022 highlighting the following: Silver production of 3.6 million ounces, an increase of 10% over the first quarter of 2022 due to record throughput at the Lucky Friday Mine, Gold production of 45,718 ounces, an increase of 10% over the first quarter, driven by better performance at the Casa Berardi mine, Zinc production increased 12% over the prior quarter & Lead production increased 23% due to increased production at Lucky Friday.

 

FURTHER AFIELD 
 
Memes stock, GameStop Corp. (GME, closed higher at $136.20, -3.60%. On July 6, GME announced a 4-1 stock split in the form of a dividend for shareholders of record at the close of business on July 18. They also announced their CFO’s departure and layoffs last week. On July 12, GameStop reportedly launched its NFT marketplace. GameStop said in its release. “The Company’s NFT marketplace is a non-custodial, Ethereum Layer 2-based marketplace that enables parties to truly own their digital assets, which are represented and secured on the blockchain. Over time, the marketplace will expand functionality to encompass additional categories such as Web3 gaming, more creators and other Ethereum environments.”
 
Shares of SIGNA Sports United N.V. (SSU), a specialist online sports retail and tech company with a focus on bike, tennis, outdoor and team sports, rose +30.82% to close at $6.42/share. On June 2, SSU reported financial results for the second quarter of fiscal year 2022 and was highlighted by their Q2 FY22 net revenue of €269 million, representing YoY growth of +48%. Q2 FY22 represents the first fiscal quarter with full contribution of recently acquired businesses WiggleCRC and Tennis Express (acquisitions closed on 14 December and 31 December 2021, respectively).
 

VP WATCHLIST UPDATES 
 
Shares of Apple (AAPL) closed at $148.47, +2.05%. Note that Apple enjoys a 6.82% weighting in the S&P 500. On July 12, for the second consecutive year, Apple TV+ broke records with 52 Emmy Award nominations across 13 titles, including Best Drama, Best Comedy, Outstanding Hosted Nonfiction Series or Special Program, Lead Actress in a Drama, Lead Actor in a Drama Series, and Lead Actor in a Comedy. In under three years after its global launch, Apple TV+ boosted its total number of Emmy Award nominations by more than 40% year-over-year. The winners of the 74th Annual Primetime Emmy Awards will be unveiled at a televised ceremony on September 12, 2022.


 
tesla
 
Shares of Tesla (TSLA) closed at $714.94, +.54%. According to a regulatory filing on June 10, Tesla has planned a 3-for-1 stock split. On July 2, Tesla reported that in the second quarter, they produced over 258,000 vehicles and delivered over 254,000 vehicles, despite ongoing supply chain challenges and factory shutdowns beyond our control. June 2022 was the highest vehicle production month in Tesla’s history. Tesla will post its financial results for the second quarter of 2022 after market close on Wednesday, July 20, 2022.Tesla management will hold a live question and answer webcast that day at 4:30 p.m. Central Time (5:30 p.m. Eastern Time) to discuss the Company’s financial and business results and outlook. Webcast: https://ir.tesla.com (live and replay)

Last Friday, July 8, Tesla CEO Elon Musk confirmed that he is terminating the buyout of Twitter (TWTR). The saga and now a lawsuit from Twitter moves forward. On July 12, Tesla’s SpaceX Starship booster reportedly exploded during prototype test, as NASA releases images from Webb telescope.

 
The Walt Disney Company (DIS) closed at $91.84, -1.18%. Marvel’s ‘Thor: Love and Thunder’ brought in $143M in its opening weekend. On July 13, The Walt Disney Company announced the six companies that will be joining the 2022 Disney Accelerator, a business development program designed to accelerate the growth of innovative companies from around the world. This year’s Disney Accelerator class is focused on building the future of immersive experiences and specializes in technologies such as augmented reality (AR), non-fungible tokens (NFTs) and artificial intelligence (AI) characters.  On July 12, Disney has reportedly also added a deal with the world-famous Korean pop band BTS, who will appear in two exclusive shows on Disney’s streaming services after the media conglomerate struck a deal with the band’s label Hybe Co.
 
 
 
Atossa Therapeutics (NASDAQ: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, rose to an intraday and closing high of $1.05, prior to closing at $1.03, -1.9% on 796,710 shares of trading volume.
 
On July 7th, Atossa filed an 8k at sec.gov that stated, that on July 1, 2022, Atossa Therapeutics, Inc. (“Atossa”) entered into a letter agreement (the “Letter Agreement”) with a venture-capital backed, private company based in the United States that is in the pre-clinical stage of developing novel Chimeric Antigen Receptor (CAR) T-cell therapies based on technology licensed from a leading U.S. adult and pediatric cancer treatment and research institution (the “CAR-T Company”). The Letter Agreement requires that up until November 1, 2022 the CAR-T Company will (i) negotiate exclusively with Atossa for Atossa to acquire the CAR-T Company, and (ii) address certain matters related to personnel, operations and intellectual property. Atossa has paid $3 million for the exclusive right to negotiate with the CAR-T Company. If a definitive agreement is not reached for Atossa to acquire the CAR-T Company and if a specified material adverse event has not occurred, then Atossa will pay an additional $2 million for a 19.99% preferred stock equity interest in the CAR-T Company. Atossa is under no obligation to complete the acquisition of the CAR-T Company and no assurance can be given that an acquisition will be completed on acceptable terms or at all.
 
On June 2nd, Atossa announced the appointment of Charles Butler, a 25-year veteran in the healthcare communications space, as vice president of investor relations and public relations. Prior to joining Atossa, Mr. Butler spent 10 years at Exelixis, Inc. where he managed all communications from the preclinical through commercial stage for multiple drugs. During his time at Exelixis, he was a part of the team that raised over $1B in equity and business development transactions. Prior to Exelixis, he worked at Ogilvy in New York and London. At Ogilvy he was part of the team that launched multiple blockbuster drugs for several pharmaceutical companies including Merck and Pfizer. While in London, he managed a 25+ person team, overseeing healthcare communications for the United Kingdom and Europe. He has also worked at Castlight Health, ICR, Adverum, Eiger Biopharmaceuticals and IN8bio, Inc. Mr. Butler graduated from George Washington University with a B.A. in Political Science.  “As Atossa continues to develop our pipeline both in breast cancer and COVID-19, the necessity for an in-house strategic manager for our communications has become an important priority and Charles’s extensive experience within the industry as a liaison for both investors and the media make him a valuable asset,” commented Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “The unique opportunity to be part of the Atossa team that is working to bring new products to market in breast cancer and other important diseases is exciting. It will allow me to leverage my many years of experience across the communications spectrum in biotechnology. I look forward to collaborating closely with management to ensure its strong message of innovation and patient care are clearly received in this crowded marketplace,” stated Charles Butler. 
 
On May 9, Atossa announced the financial results for the fiscal quarter ended March 31, 2022, and provides an update on recent company developments. Key developments from Q1 2022 and to date include: Received issuance of key U.S. patent covering Endoxifen directed to compositions of storage-stable Endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable Endoxifen, Announced planned U.S. Phase 2 clinical study of Endoxifen in the neoadjuvant setting (prior to surgery) to compare Endoxifen to standard of care in premenopausal women with breast cancer. A CRO has been engaged to work on this study and the Company also intends to retain a leading U.S. research institution to help manage the study. The Company anticipates submitting an IND to the FDA in the second quarter of 2022, Completed Part B (second of four parts) of Phase 1b/2a clinical study of AT-H201 in Australia. “We continue to make steady progress with our Endoxifen programs: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting; and another to reduce dense breast tissue in women,” commented Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “Our Phase 2 study in women with measurable breast density continues to enroll participants in Stockholm and we have been preparing to submit a request (IND) to the FDA this quarter to open a Phase 2 study in the neoadjuvant setting here in the Unites States. We began 2022 with significant progress in our COVID-19 program, both initiating and completing key parts of our Phase1b/2a trial in Australia for AT-H201, and we have now completed the first two parts of that study.” 
 
On April 20, Atossa announced it has completed enrolling participants in Part B of its Phase 1/2a clinical study of AT-H201 in Australia, consisting of multiple ascending dose cohorts in healthy participants. AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.“Part B of the study was successfully completed and, subject to approval from the ethics committee, we will now proceed to enroll the next group of participants,” said Steven Quay, M.D., Ph.D., Atossa’s CEO and President. “Despite widespread availability of vaccines, many areas of the world are seeing a recent surge in COVID-19 cases. There continues to be a strong need for additional therapies to combat COVID-19.” LEARN MORE. 
 
On March 8, Atossa announced that the U.S. Patent and Trademark office has issued a new patent further strengthening Atossa’s intellectual property in its proprietary therapy Endoxifen, which is under development for breast cancer and other breast conditions. U.S. Patent No. 11,261,151 (the ‘151 Patent) is titled “Methods for Making and Using Endoxifen” and is directed to compositions of storage-stable Endoxifen and methods of treating hormone-dependent breast disorders using the storage-stable Endoxifen. “We are very pleased with the scope and breadth of this new key patent,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “Patents covering the composition of matter of new therapies are critical to protect markets from generic competition. The ‘151 Patent,’ with its estimated expiration in 2038, strengthens our intellectual property estate and should create long-term stockholder value.” Atossa is developing its proprietary Endoxifen in two clinical settings: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting, meaning prior to surgery; and another to reduce dense breast tissue in women. A Phase 2 study is currently underway in women with measurable breast density and Atossa plans to submit a request (IND) to the FDA to open other Phase 2 in the neoadjuvant setting in the next quarter. Atossa’s neoadjuvant program is focused on breast cancers that are classified as estrogen receptor positive (ER+). Although there are numerous neoadjuvant treatments for breast cancers that are not ER+, there are few neoadjuvant treatments for ER+ breast cancer which comprises about 78% of all breast cancers. We believe there is a compelling need for therapy with our Endoxifen in this setting. An estimated ten million women in the U.S. have mammographic breast density, or MBD, for which there is no FDA-approved treatment. MBD is an emerging public health issue and studies conducted by others have shown that MBD increases the risk of developing breast cancer and that reducing MBD can reduce the incidence of breast cancer. The American Cancer Society estimates that in the U.S. in 2022, 287,850 women will be diagnosed with breast cancer, 47,550 of which will be under the age of 50 and 43,250 of which will die from the disease.
 
 
Shares of Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, closed at $31.51, +.70%.
 
On June 30, Fate announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies and solid tumors, having previously served as the Global Commercial CAR T lead at Celgene Corporation where he oversaw the commercial development strategy of the company’s CAR T-cell therapies. Mr. Powl most recently served as Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies across marketing, sales, market access and commercial operations.
 
On June 28 Fate announced that it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical Co., Ltd. (ONO) to include the development of chimeric antigen receptor (CAR) NK cell collaboration candidates. In addition, as part of the collaboration’s expansion, ONO will contribute novel binding domains targeting a second solid tumor antigen. Under the original Collaboration and Option Agreement entered into between Fate and ONO in September 2018, ONO has contributed novel binding domains targeting an initial solid tumor antigen, and Fate is currently conducting preclinical development of a multiplexed-engineered, iPSC-derived CAR T-cell product candidate for solid tumors. Under the terms of the amended Collaboration and Option Agreement, Fate will advance iPSC-derived CAR NK and CAR T-cell product candidates to a pre-defined preclinical milestone, at which point ONO has an option to assume responsibility for worldwide development and commercialization with Fate retaining the right to jointly develop and commercialize in the United States and Europe. Fate retains all rights of manufacture of collaboration products on a global basis.


 
 
 
Shares of InMed Pharmaceuticals Inc. (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, closed at $.4213/share, -1.61%, but rose to $.6479 , +~40% during the session and traded 3,704,484 shares. 

On June 14, InMed announced that a peer-reviewed scientific study entitled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes” has been published in the International Journal of Molecular Sciences. The study, in collaboration with Dr. Mauro Maccarrone, Professor and Chair of Biochemistry at the Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, Italy, highlights the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids and their potential role in addressing various skin conditions. In the peer-reviewed study, researchers analyzed the effects of rare cannabinoids THCV, CBC, cannabigerol (“CBG”) and cannabigerolic acid (“CBGA”) on the major endocannabinoid system elements in skin cells. Using a widely recognized in vitro model of human keratinocytes, researchers studied how these cannabinoids interacted with several receptors including cannabinoid receptors and other endocannabinoid system components. In summary, each cannabinoid had distinct biological activity via the endocannabinoid system. In particular, THCV was shown to perform as a cannabinoid receptor 1 (“CB1”) antagonist and have a high affinity for the human transient receptor potential vanilloid 1 (“TRPV1”), which is involved in skin sensation, as did CBC albeit to a lesser extent. The results from the study support additional research of these rare cannabinoids for their potential effect on skin conditions.“This study represents the first systematic analysis of the effects of the rare cannabinoids THCV, CBC, CBGA and CBG on the major endocannabinoid system elements using human keratinocytes. These initial observations should be considered when exploring the therapeutic potential of rare cannabinoids for the treatment of human skin disease,” said InMed’s scientific advisor, Dr. Mauro Maccarrone. “This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” said Dr. Eric Hsu, Senior VP, Preclinical Research and Development. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.” The journal article can be accessed here: https://www.mdpi.com/1422-0067/23/10/5430.

On June 9, InMed launched B2B sales of the rare cannabinoid delta 9-dominant tetrahydrocannabivarin (“d9-THCV”) into the health and wellness sector via its wholly-owned subsidiary, BayMedica LLC. Shane Johnson, MD, SVP and General Manager of BayMedica stared,  “We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio. THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike. In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high quality product. As this market continues to mature, we are well positioned to be a leading supplier of rare cannabinoids to the health and wellness industry. We currently have several high-value, rare cannabinoids in various stages of commercial development and will continue to expand our cannabinoid portfolio over the coming years”.

On June 2, InMed Pharmaceuticals Inc. announced that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the issuance and sale of 4,079,256 of its common shares at a purchase price of $0.858 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in the registered direct offering. In addition, the Company has agreed to issue to the investor in the offerings unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 5,827,506 common shares. The aggregate gross proceeds to the Company of both offerings are expected to be approximately $5 million. The offerings are expected to close on or about June 6, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offerings to continue pipeline development, advance commercial activities and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The unregistered investment options to be issued in the offerings will be exercisable immediately upon issuance at an exercise price of $0.74 per share and will expire six and one-half years from the date of issuance. The Company also has agreed that certain existing warrants to purchase up to an aggregate of 4,480,771 common shares of the Company that were previously issued to the investor, with exercise prices ranging from $2.848 to $5.11 per share and expiration dates ranging from July 2, 2026 to November 16, 2026, will be amended effective upon the closing of the registered direct offering so that the amended warrants will have a reduced exercise price of $0.74 per share, will not be exercisable until six months following the closing of the registered direct offering and will expire seven years following the closing of the registered direct offering.

On May 5, InMed announced that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 (“d-9”) dominant tetrahydrocannabivarin (“THCV”) on energy, focus/attention, appetite and weight/BMI. BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie. This rare cannabinoid, consumer-based investigation will measure the effects of the Company’s d-9 dominant THCV in a randomized, blinded, placebo-controlled study in up to 900 adult participants aged 21 and older who reside in the United States. The study includes three dosing groups including a placebo group (no THCV), each delivered via Trokie’s proprietary lozenge technology. The study is set to begin participant recruitment in May and will run for a four week period starting in June with results expected during the summer. The study is part of Radicle Science’s large scale investigations into several rare cannabinoids involving up to 10,000 participants in total, the largest of its kind to date.

On April 28, InMed announced the publication of a patent application in North America for several cannabinoid analogs. This patent application has broad claims directed to their molecular structure, uses and methods of manufacturing. Entitled “Cannabinoid Analogs and Methods for their Preparation”, the patent application describes several new cannabinoid-related chemical compounds that have not been previously described. If granted, the broad patent application allows for the creation of several variations of novel cannabinoid compounds, producing a robust library of proprietary new chemical entities (‘NCEs’). Scientists at BayMedica, LLC, InMed’s subsidiary in the US, designed and produced these cannabinoid analogs. These NCEs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases.

 
Shares of INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, closed at $.99, 3.66% and has traded up to $.9929, +.29% in the aftermarkets.
 
***INSIDER BUYING ALERT***– On Friday June 3, after the close, a number of Form 4’s were filed at www.sec.gov confirming that the CEO, COO, CFO and 5 members of the board of directors purchased shares at $.95/share on June 1, 2022. Here’s the link to view all of the share purchases. 
 
After the market closed May 16, INVO reported financial results for its first quarter 2022, ended March 31, 2022 and highlighted the following: The three INVO Centers in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico experienced a 40% increase in patient inquiries and consultations compared to the 4th quarter of 2021. This, in part, is the result of our locally targeted marketing efforts and is a positive indicator for potential treatment cycle growth in the coming periods, Announced plans to open additional INVO Centers in Tampa, Florida, and Kansas City, Missouri, in addition to the previously announced planned clinic in the San Francisco Bay Area, Signed an exclusive distribution agreement with Onesky Holdings Limited (“Onesky”) for mainland China (excludes Hong Kong, Macau and Taiwan). The exclusivity is subject to minimum annual purchase amounts over a 5-year term starting upon product registration, the cost of which is to be borne by Onesky, Processed initial product orders from direct sales to U.S. IVF clinics and engaged with approximately 80 clinics, including both new relationships and those already trained on the INVOcell and IVC by Ferring, & Received product orders from our Spain, Pakistan and Nigeria partnerships.
 
On April 28, INVO announced that in celebration of this year’s National Infertility Awareness Week (“NIAW”), three eligible patients will be granted a full IVC treatment cycle free of charge. The grant program, including patient selection, will be launched in the coming weeks. NIAW is a movement, founded in 1989 by RESOLVE, with a mission to empower patients and help those struggling to build a family. “We are committed to helping people suffering with infertility challenges have access to effective and affordable care,” stated Steve Shum, INVO CEO. “This grant program will benefit selected recipients and is part of our efforts to build awareness and educate patients on INVOcell as an effective and available treatment. We believe our INVOcell technology and the IVC treatment can provide an affordable solution for patients diagnosed with infertility, and can help address key industry challenges regarding cost, capacity constraints and access to care for the large, underserved patient population. We have three operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with others scheduled to open in the San Francisco, Tampa and Kansas City areas later this year. In collaboration with our partners in Atlanta, we are pleased to offer this grant program and encourage people with fertility challenges to reach out to our INVO Center to check eligibility and receive details.” Bloom Fertility, an INVO Center, 6 Concourse Parkway, Suite 250., Atlanta, GA 30328, Ph 678-597-9933, hellobloomfertility.com.
 
 
 
Shares of NeuBase Therapeutics (NASDAQ: NBSE), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, closed at $.9980, -2.161%.  The 52-wk range is $.77-$5.08.
 
On June 29, NBSE announced the promotion of William (Bill) Mann, Ph.D. to President of the Company, effective immediately. Dr. Mann will also continue to serve as NeuBase’s Chief Operating Officer. “Since joining NeuBase as our Chief Operating Officer in July 2020, Dr. Mann has played an integral role in the advancement of the Company’s PATrOL™ platform and pipeline of therapeutic programs to treat myotonic dystrophy type 1, Huntington’s disease, and KRAS-driven cancers,” said Dietrich A. Stephan, Ph.D., Founder, Chief Executive Officer, and Chairman of NeuBase. “I look forward to continuing our work together as we employ NeuBase’s platform to design and develop novel genetic medicines that target and rescue gene dysfunctions and drive clinically impactful outcomes in rare and common diseases.”Prior to joining NeuBase, Dr. Mann served as the President, CEO, and board member of Helsinn Therapeutics U.S., where he transformed the development-focused company into a profitable commercial entity with a portfolio that included Aloxi®, Akynzeo®, Halaven®, and Zykadia®. Prior to Helsinn, he was Vice President of Corporate Development at Sapphire Therapeutics, where he led several business development transactions, including the licensing of anamorelin to Ono Pharmaceutical Co, Ltd., and played a key role in the sale of the company to Helsinn Healthcare SA. Also in this role, Dr. Mann managed the international Phase 2B study of anamorelin, which is now approved in Japan as Adlumiz® for the treatment of cancer cachexia. Dr. Mann began his professional career at Novartis, where he led a multidisciplinary drug discovery program and later served as Director of Business Development. He received bachelor and doctorate degrees in biochemistry from the University of Aberdeen, Scotland, completed postdoctoral studies at The Rockefeller University, and obtained an MBA from Rutgers University.
 
On May 17, Neubase announced the presentation of preclinical pharmacokinetics (PK) and biodistribution data for its lead development candidate, NT-0231.F, supporting a differentiated whole body treatment solution for myotonic dystrophy type 1 (DM1). These new data are being presented today in a poster session at the American Society of Gene and Cell Therapy (“ASGCT”) 25th Annual Meeting, taking place virtually and in person in Washington, D.C., May 16-19, 2022. Following a single intravenous (IV) injection of 30 mg/kg in wild-type BALB/c mice, NT-0231.F was cleared rapidly from the systemic compartment and demonstrated rapid and wide distribution into tibialis anterior muscle, heart muscle, and brain tissues. NT-0231.F rapidly cleared the plasma, and each tissue evaluated displayed an extended elimination phase with tissue concentrations measurable for at least four weeks following a single IV dose administration. Sandra Rojas-Caro, M.D., Chief Medical Officer of NeuBase, said, “We continue to build a robust and compelling data set potentially supporting a whole body treatment solution for DM1. These PK and biodistribution data presented today show IV administration of our lead candidate results in exposure in the major tissues that are affected by DM1. We believe the ability of our drug candidate to reach skeletal and heart muscles as well as brain tissue may potentially deliver a differentiated therapeutic approach to not only treat the myotonia, muscle weakness, and cardiac effects but also the cognitive impairments seen in DM1. We have now demonstrated in preclinical models that our lead candidate NT-0231.F achieves clinically relevant molecular and functional rescue as well as whole-body distribution.”
 
INmune Bio
 

INmune Bio, Inc. (INMB) closed at $9.86, -5.56%. On June 22, INmune Bio announced the issuance of U.S. Pat. No. 11,365,229 for “METHODS OF TREATING NEUROLOGICAL DISEASES,” a patent directed to use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as the Company’s XPro™, by peripheral administration for crossing the blood-brain barrier (BBB) and treating diseases of the Central Nervous System (CNS). The patent is currently set to provide coverage through September 10, 2033, subject to a possible patent term extension if requested by the Company and approved by the USPTO under 35 U.S.C. 156.

Shares of Chinook Therapeutics, Inc. (KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, closed at $18.90, +.32%.

On July 5, KDNY announced that the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). Orphan drug designation is granted to medicines that are intended to treat, prevent or diagnose a life-threatening or chronically debilitating rare disease with a prevalence in the European Union (EU) of fewer than five in 10,000 and with either no currently approved method of diagnosis, prevention or treatment or with significant benefit to those affected by the disease. Orphan designation in the EU provides sponsors with incentives including protocol assistance, 10 years of market exclusivity after approval and reductions in regulatory fees.


Economic Reports

On Monday, no economic data reports surfaced on July 4th holiday.

On Tuesday, the June NFIB Small Business Optimism report confirmed that it came in at 89.5 representing the lowest reading in 9 years!

On Wednesday, the total CPI for June came in at 9.1% and the core CPI was up 5.9% further inflaming the worries that the Fed will need to raise interest rates in July to tame inflation. The macroeconomic schedule also produced the Weekly MBA Mortgage Applications report that confirmed a 1.7% drop. The Crude oil inventories report also confirmed a 3.25M barrels buildup in concert with the gasoline inventories report that also showed a buildup of 5.83M barrels. Oil prices dropped .9% to close at  $96.38/bbl. The Treasury Budget report also confirmed a $88.8B deficit in June. The Fed’s June Beige Book also showed an overall modest economic expansion since May, however a number of Districts confirmed signs of a slowdown plus a fears recession, but still coupled with a rise in prices.

 

Investing & Inspiration

  1. “History is a vast early warning system.” – Norman Cousins 

  2. “We first make our habits, and then our habits make us.” – John Dryden

  3. “The traveler sees what he sees, the tourist sees what he has come to see.” – Gilbert K. Chesterton
  4. “Adventure is worthwhile.” – Aesop
  5. “We must build dikes of courage to hold back the flood of fear.” – Martin Luther King, Jr.
  6. “The return we reap from generous actions is not always evident.” – Francesco Guicciardini
  7. “Courage is knowing what not to fear.” – Plato

  8. “Science may never come up with a better office communication system than the coffee break.” – Earl Wilson

  9. “Progress was all right. Only it went on too long.” – James Thurber

  10. “If you would know strength and patience, welcome the company of trees.” – Hal Borland

  11. “We aim above the mark to hit the mark.” – Ralph Waldo Emerson
  12. “Hope is being able to see that there is light despite all of the darkness.” – Desmond Tutu

  13. “Our chief want is someone who will inspire us to be what we know we could be.” – Ralph Waldo Emerson

  14. “Patience is a virtue, and I’m learning patience. It’s a tough lesson.” – Elon Musk

  15. “Great things are done when men and mountains meet.” – William Blake

  16. “The man who has no imagination has no wings.” – Muhammad Ali

  17. “Formula for success: rise early, work hard, strike oil.” – J. Paul Getty

  18. “Action is the foundational key to all success.” – Pablo Picasso

  19. “Hope is like the sun, which, as we journey toward it, casts the shadow of our burden behind us.” – Samuel Smiles

    “The backbone of surprise is fusing speed with secrecy.” – Carl von Clausewitz

  20. “There are no shortcuts in evolution.” – Louis D. Brandeis

  21. “I am fascinated by what is beautiful, strong, healthy, what is living. I seek harmony.” – Leni Riefenstahl
  22. “If one advances confidently in the direction of his dreams, and endeavors to live the life which he has imagined, he will meet with a success unexpected in common hours.” – Henry David Thoreau
  23. “Waste no more time arguing about what a good man should be. Be one.” – Marcus Aurelius
  24. “It is during our darkest moments that we must focus to see the light.” – Aristotle Onassis
  25. “Courage is fear holding on a minute longer.” – George S. Patton
  26. “You must be the change you wish to see in the world.” – Mahatma Gandhi
  27. “Don’t judge each day by the harvest you reap but by the seeds that you plant.” – Robert Louis Stevenson 
  28. “It is in the character of very few men to honor without envy a friend who has prospered.” – Aeschylus
  29. “Life is a series of natural and spontaneous changes. Don’t resist them – that only creates sorrow. Let reality be reality. Let things flow naturally forward in whatever way they like.” – Lao Tzu
  30. “The more you praise and celebrate your life, the more there is in life to celebrate.” – Oprah Winfrey
  31. “Anything simple always interests me.” – David Hockney
  32. “He who angers you conquers you.” – Elizabeth Kenny
  33. “Concision in style, precision in thought, decision in life.” – Victor Hugo
  34. “The secret of genius is to carry the spirit of the child into old age, which means never losing your enthusiasm.” – Aldous Huxley
  35. “View health as an investment, not an expense.” – John Quelch
  36. “The most effective way to do it, is to do it.” – Amelia Earhart
  37. “Man needs his difficulties because they are necessary to enjoy success.” – A. P. J. Abdul Kalam
  38. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha
  39. “Nobody made a greater mistake than he who did nothing because he could do only a little.” – Edmund Burke
  40. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  41. “Success is dependent on effort.” – Sophocles
  42. “Nobody who ever gave his best regretted it.” – George Halas
  43. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  44. “And when I breathed, my breath was lightning.” – Black Elk
  45. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  46. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  47. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  48. “We are an impossibility in an impossible universe.” – Ray Bradbury
  49. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  50. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  51. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  52. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  53. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  54. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  55. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  56. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  57. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  58. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  59. “There is more to life than increasing its speed.” – Mahatma Gandhi
  60. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  61. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  62. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  63. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  64. “Life is too short for long-term grudges.” – Elon Musk
  65. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  66. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  67. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  68. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  69. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  70. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  71. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  72. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  73. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  74. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  75. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  76. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  77. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  78. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  79. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  80. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  81. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  82. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  83. “Delete the negative; accentuate the positive!” – Donna Karan
  84. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  85. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  86. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  87. “Everything has beauty, but not everyone sees it.” – Confucius
  88. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  89. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  90. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  91. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  92. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  93. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  94. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  95. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  96. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  97. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  98. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  99. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  100. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  101. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  102. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  103. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  104. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  105. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  106. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  107. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  108. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  109. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  110. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  111. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  112. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  113. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  114. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  115. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  116. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  117. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  118. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  119. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  120. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  121. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  122. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  123. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  124. “The secret of getting ahead is getting started.” – Mark Twain
  125. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos